The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 22, 2015

Filed:

Aug. 03, 2012
Applicants:

Takashi Kohno, Tokyo, JP;

Koji Tsuta, Tokyo, JP;

Inventors:

Takashi Kohno, Tokyo, JP;

Koji Tsuta, Tokyo, JP;

Assignees:

National Cancer Center, Toyko, JP;

LSIP, LLC, Tokyo, JP;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 31/4412 (2006.01); C07K 14/82 (2006.01); G01N 33/574 (2006.01); C12Q 1/68 (2006.01); A61K 31/517 (2006.01); C12N 9/12 (2006.01); C12N 9/14 (2006.01); A61K 31/44 (2006.01); C07K 14/71 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4412 (2013.01); A61K 31/44 (2013.01); A61K 31/517 (2013.01); C07K 14/71 (2013.01); C07K 14/82 (2013.01); C12N 9/1205 (2013.01); C12N 9/14 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57407 (2013.01); G01N 33/57423 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); G01N 2800/52 (2013.01);
Abstract

In order to identify a gene that can serve as an indicator for predicting the effectiveness of a drug treatment of cancer and to provide a novel method for predicting the effectiveness of a drug treatment targeting said gene, lung adenocarcinomas were subjected to whole-transcriptome sequencing. As a result, in-frame fusion transcripts between the KIF5B gene and the RET gene were identified. The KIF5B-RET gene fusions were detected in 6 out of 319 (2%) LADC specimens from Japanese individuals and 1 out of 80 (1%) LADC specimens from U.S.A. individuals. None of the seven subjects revealed known activating mutations such as EGFR, KRAS or ALK oncogenes; thus, said gene fusions were found to be responsible mutations (driver mutations) for oncogenesis. Since said gene fusions are considered to induce constitutive activation of RET tyrosine kinase protein, it was found that treatments with RET tyrosine kinase inhibitors are effective in patients with detection of said gene fusions.


Find Patent Forward Citations

Loading…